Project Grant R01TW008145

This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) provides $780,853 to the University of Pittsburgh to investigate the impact of a glucagon-like peptide-1 receptor agonist on SIV/HIV pathogenesis and antiretroviral therapy (ART) in people living with HIV. The primary objectives are to assess changes in T-cell and macrophage metabolism, immune cell function, and...

This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (CFDA 93.847 - Diabetes, Digestive, and Kidney Diseases Extramural Research) aims to investigate the mechanisms by which integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) leads to weight gain, particularly in females. The $707,929 award to The Johns Hopkins University will fund a multidisciplinary, translational research effort to: 1) define the molecular pathways by...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $153,912 to the University of Ghana Medical Centre to conduct research on the pharmacokinetics and pharmacogenomics of dolutegravir-based antiretroviral therapy in young people living with HIV in Ghana. The key objectives of this research project are to: 1) Determine rates of dolutegravir-based antiretroviral therapy...

This $375,000 federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) aims to evaluate the impact of a status-neutral, person-centric intervention called the "Blue Shed" on HIV transmission and outcomes among people who inject drugs (PWID) in New Delhi, India. The project has three key objectives: Assess the direct impact of the Blue Shed intervention on HIV incidence, viral suppression, and mortality among PWID...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, is funding a $3,356,188 research project titled "IMPACT OF NEONATAL ART AND BROADLY NEUTRALIZING ANTIBODIES ON HIV-1 RESERVOIRS IN INFANTS: TOWARDS ART-FREE REMISSION." The project aims to characterize the HIV-1 proviral pool composition in neonates and infants receiving very early and enhanced early antiretroviral...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,314,701.00 to support research focused on optimizing dolutegravir-based antiretroviral therapy (ART) in children and adolescents. The primary award recipient is the University of Florida, which will oversee the overall research project. The project includes sub-awards to Kwame Nkrumah University of Science...

This federal Project Grant award under the Child Health and Human Development Extramural Research program (CFDA 93.865) at the National Institute of Child Health and Human Development will support research on the impact of dolutegravir (DTG)-based antiretroviral therapy (ART) regimens on appetite regulation and weight management in postpartum women living with HIV and their HIV-exposed uninfected (HEU) infants. The total funding amount is $262,105 for the project period from August 6, 2024 to...

This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to comprehensively investigate the extent and impact of transmitted and acquired HIV drug resistance in Kenya as the country transitions to widespread use of dolutegravir-based antiretroviral therapy. The $645,900 award, with a project period from September 2024 to July 2029, will fund a prospective study to...

The National Institute of Allergy and Infectious Diseases (NIAID) has awarded Colorado State University a $340,408 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate an assay for precision antiretroviral therapy to combat drug resistance in HIV patients. The key products and services to be delivered under this award include: Improving the throughput and capacity of an existing infectivity assay using proviral constructs with an H2B-mRFP...

This federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $534,721 to Oregon Health & Science University to study the impact of antiretroviral therapy (ART) on fetal immune system development in a rhesus macaque model of simian immunodeficiency virus (SIV) infection. The research aims to determine the effects of maternal SIV/ART or ART alone on fetal immune system function...